China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released a...
Fineline Cube
Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience
Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated...
China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations
China’s National Medical Products Administration (NMPA) released the Administrative Measures for Medical Device Online Sales...
China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units
China’s National Drug Joint Procurement Office released enterprise-related information for the 12th batch of national...
HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
HBM Holdings Limited (HKG: 2142) announced a strategic cooperation framework agreement with China National Pharmaceutical...
Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
Antengene Corporation Limited (HKG: 6996) announced preliminary financial results for the six months ended June...
China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient...
Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
Broncus Medical Inc. (HKG: 2216) announced that its self-developed BroncTru disposable bronchoscopic dilation catheter has...
CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...
Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate...
CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its...
Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical...
InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial
InnoCare Pharma (HKG: 9969) announced that the pivotal Phase III clinical trial of its potent,...
Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that HRS-1780 tablets have received...
Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that BIOS0635-048 tablets have received approval from...
GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced results from the Phase IIIb VOGUE study conducted by...
Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC),...
AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds
AstraZeneca plc (NYSE: AZN) announced financial results for the second quarter and first half of...
Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend
Alexion, AstraZeneca plc’s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III...
Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data
Sanofi S.A. (NASDAQ: SNY) announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal...